AVOID METASTATIC DISEASE

CASE DESCRIPTION

- Tumour with high probability to form metastasis
- Documented infiltration of tumour cells into lymphatic system
- Documented tumour cells in lymph node

FOR EXAMPLE

- Mammary adenocarcinoma – with lymphoid involvement
- Hemangiosarcoma of the spleen with blood effusion
- Melanoma (i.e. digital/nail melanoma)
- Osteosarcoma

CLASSICAL ONCOLOGIC APPROACH

Chemotherapy

PROBLEM

Owner does not want chemotherapy in order to treat metastatic disease.

SOLUTION

Use dendritic cell therapy in order to reduce risk of metastasis.

PROCEDURE

1. Perform surgery in order to reduce tumour mass.
2. Follow-Up: Result of patho-histo report shows suspicion of metastatic disease
3. Start with dendritic cell therapy immediately in order to reduce risk of metastasis.
4. Perform three applications of dendritic cells in a 4 week interval.
5. Monitor patient in narrow intervals (3 months)
6. Treat with dendritic cells every three to six months

PetBioCell

AVOID METASTATIC DISEASE – CASE STUDIES

A recent evaluation of dogs treated with dendritic cell therapy from 2010 to 2015 with hemangiosarcoma of the spleen stages II and III revealed the following data:
The mean survival time was 701 days, with a median survival (half of the dogs were still alive) of 458 days.

Source: Dr. Thomas Grammel (2016) – A pilot, uncontrolled study of postsurgical treatment with autologous dendritic cell-based immunologic therapy in 10 dogs with splenic hemangiosarcoma, 3rd World Veterinary Conference, Foz do Iguassu / Brazil, May 25-29, 2015

Two of 17 bitches developed lung metastasis from a mammary adenocarcinoma with intrusion into the lymphatic system.

Source: Dr. Thomas Grammel (2017) – A Pilot uncontrolled study of postsurgical treatment with autologous dendritic cell-based immunologic therapy in 17 dogs with mammary adenocarcinoma

MELANOMA OF THE EYE

The amelanotic malignant melanoma was removed through surgery.
The patient was treated with dendritic cells, no metastasis occurred.



OSTEOSARCOMA

Use of dendritic cell therapy after the amputation of the osteosarcoma in order to avoid the formation of metastases.

PetBioCell GmbH · Schillerstraße 17 · 37520 Osterode am Harz · Germany
phone +49 5522 9182581 · email info@petbiocell.com · web www.petbiocell.com